Investor Type | Firm |
Industries | HealthTech (& Fitness) • Healthcare (& Wellness) • Woman Focused |
Stages | Pre-Seed, Seed |
Investing | United States • Canada |
Investment Range | $50,000 - $250,000 |
Investment Sweet Spot | $100,000 |
Beckley Waves is an investment fund that specializes in the HealthTech, Healthcare, Wellness, and Women-Focused industries with an emphasis on the emerging psychedelic field. Their core mission is to expand access to psychedelic treatments and support the infrastructure for a global psychedelic ecosystem. They engage in pre-seed and seed-stage investments with a typical investment range of $50,000 to $250,000 and a sweet spot of around $100,000. Their efforts are rooted in the work of co-founder and chair Amanda Feilding, who has pioneered scientific research through the Beckley Foundation, contributing to the understanding and development of psychedelic compounds for mental health treatment. Beckley Waves operates as a venture studio, incubating companies and investing in startups that are aligned with their mission to provide lawful and impactful psychedelic-assisted treatments. They aim to foster safety, access, and responsibility in the use of psychedelics, emphasizing the importance of ethical and legal practices. The company also prioritizes investing in high-integrity leaders who can advance human wellbeing and consciousness. By adopting an ethos of safety, access, and responsibility, Beckley Waves invests in platforms and products that enable equitable access to psychedelic therapies and experiences. Their incubation process involves founding new companies while their investment strategy focuses on transformative offerings in the psychedelic market. The impact they seek is the establishment of foundational infrastructure supporting the responsible use of psychedelics. Becky Waves is also associated with Beckley Psytech, which develops a pipeline of psychedelic compounds for treatment of neurological and psychiatric disorders. They co-found or partner with teams providing safe and legal access to psychedelic medicines and mental health solutions, continually building on the legacy of Amanda Feilding and exploring the business, science, and policy of psychedelics with their publication The Trip Report.